Brain concussion
Drug research and approvals for brain concussion: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 113 studies of brain concussion are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 113
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 113 recruiting on ClinicalTrials.gov ↗- Rehabilitation Through Virtual Immersion & Integrated Exposure for Mild Traumatic Brain Injury (ReVIVE for mTBI)NCT07890337 · Phase 1 · Johns Hopkins University · starts Nov 1, 2026
- Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain InjuryNCT07935278 · Phase 2 · HealthPartners Institute · starts Nov 1, 2026
- The PIONEER Comparative Effectiveness Study - Project 2NCT07829107 · Not applicable · University of Michigan · starts Oct 15, 2026
- Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain InjuryNCT03655782 · Not applicable · Perception Dynamics Institute · starts Oct 5, 2026
- Hyperbaric Oxygen Therapy for Veterans With TBI and PCS: A Biomarker StudyNCT07849465 · Phase 2 · Summit Hyperbarics and Wellness · starts Oct 1, 2026
- Group-based Emotional Awareness and Expression Therapy to Support Recovery After Acquired Brain Injury: A Clinical…NCT07852936 · Not applicable · Uppsala University · starts Sep 15, 2026
- HBOT Effects on First Responders' Cognition and Well-BeingNCT07852728 · Phase 2 · Summit Hyperbarics and Wellness · starts Sep 11, 2026
- Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 2NCT07796074 · Phase 2 · Yale University · starts Sep 1, 2026
- Examining the Efficacy of the Man Therapy Platform in Reducing Problematic Anger Among Military Service Members With…NCT07604701 · Not applicable · University of Colorado, Denver · starts Sep 1, 2026
- BCAAs in Concussion 3.0NCT07670195 · Phase 2 · Akiva Cohen · starts Aug 5, 2026
Drug Pipeline
1 in phase 3, 8 in phase 2, 5 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Quetiapine
- Phase 3 Serotonin 2a (5-HT2a) receptor antagonist
- Magnesium oxide
- Phase 2
- Sildenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Icosapent
- Phase 2 Unknown
- Trofinetide
- Phase 2 Unknown
- Fish oil
- Phase 2 Supplement
- Oxygen
- Phase 2 Essential for cellular homeostasis
- Riboflavin
- Phase 2
- Ghrelin
- Phase 2
- Lithium carbonate
- Phase 1 Inositol-1(or 4)-monophosphatase 1 inhibitor
- Doconexent
- Phase 1
- Resveratrol
- Phase 1
- Acetaminophen
- Early phase 1 Cyclooxygenase inhibitor
- Ondansetron
- Early phase 1 Serotonin 3a (5-HT3a) receptor antagonist
How Its Trials Ended
452 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 77 whose ending is known, 31% met their primary endpoint, 6% missed it and 62% stopped early.
- Completed, result not reported18741%
- Ongoing13630%
- Status unknown5212%
- Stopped: other or unclear307%
- Met its primary endpoint245%
- Stopped: enrollment or feasibility112%
- Missed its primary endpoint51%
- Stopped: funding41%
- Stopped: sponsor or business decision20%
- Stopped: lack of efficacy10%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA